Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Maraveyas

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 2, 1999
Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytesA Maraveyas, B Baban, D Kennard, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
British Journal of Cancer|August 13, 2009
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 StudyJ W Valle, H Wasan, P Johnson, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
Journal of Thrombosis and Haemostasis : JTH|October 16, 2015
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patientsT van der Hulle, P L den Exter, B Planquette, et al.
Thrombosis Research|June 5, 2023
Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support toolJ Goedegebuur, D Abbel, S Accassat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 2, 1999
Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytesA Maraveyas, B Baban, D Kennard, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
British Journal of Cancer|March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigationsA Azzabi, A N Hughes, P M Calvert, et al.
British Journal of Cancer|August 13, 2009
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 StudyJ W Valle, H Wasan, P Johnson, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
Journal of Thrombosis and Haemostasis : JTH|October 16, 2015
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patientsT van der Hulle, P L den Exter, B Planquette, et al.
Thrombosis Research|June 5, 2023
Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support toolJ Goedegebuur, D Abbel, S Accassat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 4